RedHill Biopharma Ltd.
RDHL
$2.07
-$0.065-3.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.04M | 5.88M | 3.71M | 4.22M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.04M | 5.88M | 3.71M | 4.22M | -- |
| Cost of Revenue | 3.19M | 2.82M | 2.45M | 2.55M | -- |
| Gross Profit | 4.85M | 3.06M | 1.26M | 1.67M | -- |
| SG&A Expenses | 15.52M | 18.24M | 20.97M | 24.55M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -535.50K | -1.07M | -4.98M | -- |
| Total Operating Expenses | 20.30M | 22.25M | 24.20M | 24.89M | -- |
| Operating Income | -12.25M | -16.37M | -20.49M | -20.67M | -- |
| Income Before Tax | -8.27M | -19.22M | -30.17M | -27.87M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.27 | -19.22 | -30.17 | -27.87 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.27M | -19.22M | -30.17M | -27.87M | -- |
| EBIT | -12.25M | -16.37M | -20.49M | -20.67M | -- |
| EBITDA | -11.73M | -15.69M | -19.51M | -19.11M | -- |
| EPS Basic | -66.46K | -393.21K | -719.97K | -647.29K | -- |
| Normalized Basic EPS | -3.01 | -22.82 | -42.63 | -138.86 | -- |
| EPS Diluted | -66.46K | -393.21K | -719.97K | -647.29K | -- |
| Normalized Diluted EPS | -3.01 | -22.82 | -42.63 | -138.86 | -- |
| Average Basic Shares Outstanding | 4.93M | 4.03M | 3.13M | 2.08M | -- |
| Average Diluted Shares Outstanding | 400.00 | 300.00 | 200.00 | 100.00 | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |